Jean-Francois Timsit
Overview
Explore the profile of Jean-Francois Timsit including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
532
Citations
12414
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kachaner A, Mageau A, Timsit J, Rio J, Papo T, Sacre K
Autoimmun Rev
. 2025 Mar;
24(6):103802.
PMID: 40081727
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease that typically affects women of childbearing age. Using a nationwide database, we aimed to assess the prevalence, main clinical features and...
2.
Antcliffe D, Peronnet E, Pene F, Stralin K, Brealey D, Blein S, et al.
Crit Care
. 2025 Mar;
29(1):98.
PMID: 40033354
Background: Sepsis gene-expression sub-phenotypes with prognostic and theranostic potential have been discovered. These have been identified retrospectively and have not been translated to methods that could be deployed at the...
3.
Barbier F, Buetti N, Dupuis C, Schwebel C, Azoulay E, Argaud L, et al.
Crit Care Med
. 2025 Feb;
PMID: 40009040
Objectives: To evaluate whether early appropriate antimicrobial therapy (EAAT) is associated with improved outcomes in critically ill patients with hospital-acquired pneumonia (HAP), ventilated HAP (vHAP), or ventilator-associated pneumonia (VAP) involving...
4.
Bhowmick T, Canton R, Pea F, Quevedo J, Santerre Henriksen A, Timsit J, et al.
Future Microbiol
. 2025 Feb;
:1-10.
PMID: 40007489
Cefepime-enmetazobactam is a β-lactam/β-lactamase inhibitor (BL/BLI) combination that has demonstrated potent activity against extended spectrum beta-lactamase (ESBL)-producing Enterobacterales, recently approved by the US FDA for the treatment of complicated urinary...
5.
Sonneville R, de Montmollin E, Contou D, Ferrer R, Gurjar M, Klouche K, et al.
Intensive Care Med
. 2025 Jan;
51(2):454-455.
PMID: 39841213
No abstract available.
6.
Thy M, Sonneville R, Ruckly S, Mourvillier B, Schwebel C, Cohen Y, et al.
J Intensive Care
. 2025 Jan;
13(1):5.
PMID: 39810227
Background: Sepsis-associated encephalopathy (SAE) may be worsened by early systemic insults. We aimed to investigate the association of early systemic insults with outcomes of critically ill patients with severe SAE....
7.
Hoffman T, Margalit I, Tabah A, Ruckly S, Barbier F, Singer P, et al.
Infect Dis Ther
. 2025 Jan;
14(2):483-492.
PMID: 39794673
Introduction: We aimed to investigate risk factors for mortality among older adults (≥ 75 years) with hospital-acquired bloodstream infections (HA-BSI) in the intensive care unit (ICU). Methods: We included patients...
8.
Genovese C, Mahida B, Rouzet F, Timsit J, Thy M
Intensive Care Med
. 2025 Jan;
51(2):418-420.
PMID: 39774868
No abstract available.
9.
Viermyr H, Tonby K, Ponzi E, Trouillet-Assant S, Poissy J, Arribas J, et al.
EBioMedicine
. 2024 Dec;
111():105511.
PMID: 39731852
Background: The Bari-SolidAct randomized controlled trial compared baricitinib with placebo in patients with severe COVID-19. A post hoc analysis revealed a higher incidence of serious adverse events (SAEs) among SARS-CoV-2-vaccinated...
10.
Tamisier R, Philippe C, Prigent A, Charley-Monaca C, dOrtho M, Gentina T, et al.
Chest
. 2024 Dec;
PMID: 39710250
Background: A large number of symptomatic individuals with central sleep apnea (CSA) in clinical practice have an indication for adaptive servoventilation (ASV) therapy. Research Question: What are the effects of...